Table 1 Patients baseline characteristics
From: Hyperbaric oxygen therapy effects on pulmonary functions: a prospective cohort study
Total | Males | Females | Significance | |
|---|---|---|---|---|
N | 88 (100%) | 55 (62.5%) | 33 (37.5%) | |
Age (years) | 60.36 ± 15.43 | ±11.26 65.13 | 52.41 ± 18.15 | 0.0001 |
Height (cms) | 170.72 ± 9.72 | 175.63 ± 6.54 | 162.54 ± 8.62 | < 0.0001 |
Weight (kgs) | 75.20 ± 14.69 | 81.94 ± 13.16 | 63.96 ± 9.29 | < 0.0001 |
BMI | 25.67 ± 3.79 | 26.54 ± 3.85 | 24.25 ± 3.28 | 0.005 |
Chronic medical conditions | ||||
Diabetes mellitus | 17 (19.3%) | 15 (27.3%) | 2 (6.1%) | 0.015 |
Hypertension | 26 (29.5%) | 22 (40%) | 4 (12.1%) | 0.006 |
Hypercholesterolemia | 26 (29.5%) | 21 (38.2%) | 5 (15.2%) | 0.022 |
Ischemic heart disease | 13 (14.8%) | 13 (23.6%) | 0 | 0.001 |
Pulmonary disease | 5 (5.7%) | 5 (9.1%) | 0 | 0.15 |
History of smoking | 27 (30.7%) | 21 (38.2%) | 6 (18.8%) | 0.059 |
Pack years (in smokers) | 18.33 ± 13.95 | 19.31 ± 15.15 | 14.91 ± 8.72 | 0.51 |
Indication | 0.707 | |||
Neurological | (65.9%) 58 | 36 (65.4%) | 22 (66.6%) | |
Wounds/Radiation | 6 (8.4%) | 3 (5.5%) | 3 (9.1%) | |
Other | 24 (27.3%) | 16 (29.0%) | 8 (24.2%) | |
Medications | ||||
Anti-aggregation | 27 (30.7%) | 21 (38.2%) | 6 (18.2%) | 0.049 |
ACE-Inhibitors | 17 (19.3%) | 15 (27.3%) | 2 (6.1%) | 0.023 |
Statins | 34 (38.6%) | 27 (49.1%) | 7 (21.2%) | 0.009 |
Proton pump inhibitors | 12 (13.6%) | 9 (16.4%) | 3 (9.1%) | 0.336 |
Baseline Pulmonary functions | ||||
FEV1 | 2.83 ± 0.73 | 2.97 ± 0.77 | 2.60 ± 0.61 | 0.022 |
FVC | 3.55 ± 0.97 | 3.79 ± 0.96 | 3.15 ± 0.87 | 0.002 |
FEV1/FVC | 80.10 ± 9.64 | 78.44 ± 10.1 | 82.87 ± 8.26 | 0.036 |
PEF | 5.74 ± 1.88 | 6.87 ± 2.0 | 5.11 ± 1.57 | < 0.001 |